Respiratory mist inhaler linked to higher deaths: BMJ

A mist inhaler that delivers a widely-prescribed respiratory drug increases the risk of dying by half, according to a paper published on Tuesday by the British Medical Journal (BMJ).

Researchers in Britain and the United States looked at five trials involving Respimat, an inhaler that delivers in a low-dosage mist a medication which can be alternatively taken in powdered form.

The study's findings have been contested by the German maker and an outside commentator noted that, in absolute terms, the number of deaths was very low.

The drug, tiotropium bromide, which is commercialised as Spiriva, relaxes muscles in the airways. It is designed to ease symptoms of chronic obstructive respiratory disease (COPD), the world's fourth leading cause of death.

The study was an overview of five trials in which patients, chosen at random, used Respimat, breathing in either Spiriva or a placebo.

A total of 6,522 patients were enrolled, 3,686 of whom used the drug and 2,836 used the lookalike. Two trials lasted 12 weeks while the others were long term, lasting one year.

The risk of death among patients using Respimat with Spiriva was 52 percent higher than in a placebo group, according to the paper, basing this estimate on data from long-term use.

The risk, it suggests, could be cardiovascular.

Tiotropium belongs to a class of drugs called anticholinergics, which increase the risk of heart rhythm disturbance, especially in those with a history of cardiac problems.

"What we think is going on is that the mist inhaler is delivering a higher concentration of tiotropium than it should be and that may be increasing the risk of death," said Sonal Singh, an assistant professor of internal medicine at Johns Hopkins University School of Medicine and lead author of the study.

The study did not look at the powdered form of Spiriva, which is administered in a daily dose of 18 microgrammes through a device called a HandiHaler.

Respimat delivers Spiriva as a mist in either five or 10 microgramme doses. In the review, 847 participants, in four of the trials, received the 10 microgramme dose; their risk of death was twice that of the placebo group.

Previous studies have indicated that blood-level concentrations of Spiriva, at five or 10 microgrammes, can be between 35 percent and 300 percent higher when compared with the 18-microgramme dose from the HandiHaler, according to the BMJ review.

Asked by AFP to respond, the German pharmaceutical firm Boehringer Ingelheim said it disagreed with the study's conclusions.

Clinical tests, it said, showed mortality rates "were within the range of other COPD trials" and data about the product's risks and benefits were well established.

It also pointed at what it called the limitations of the analysis, noting that the authors themselves said their estimates could be "imprecise owing to the fairly low incidence rates."

This argument was also put forward in a BMJ editorial written by specialist Christopher Cates of St. George's University of London medical school.

In absolute terms, "death was a rare event" in the five trials, he noted. Statistically, for every 1,000 patients treated for a year, 18 would die in the placebo group and 26 in the Spiriva group.

More than 55 countries have licenced the Spiriva Respimat, although the device has yet to gain regulatory approval in the US.

A 17,000-patient study is underway in several countries comparing the HandiHaler and the Respimat.

Pending its outcome, "the indirect evidence" is that Handihaler is safer than the Respimat, and if patients have a strong preference for the mist inhaler, "the possible increased risk" should be explained to them, Cates said.

COPD, a term including chronic bronchitis and emphysema, kills more than three million people each year, many as a result of smoking.



Life and Style
ebookNow available in paperback
ebookA delicious collection of 50 meaty main courses
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Recruitment Genius: Project Coordinator

    £28000 - £30000 per annum: Recruitment Genius: A Project Coordinator is requir...

    Recruitment Genius: Area Sales Manager - Midlands

    £20000 - £25000 per annum: Recruitment Genius: This is an exciting opportunity...

    Recruitment Genius: PHP Developer - 3-4 Month Fixed Contract - £30-£35k pro rata

    £30000 - £35000 per annum: Recruitment Genius: This is a 3-4 month pro rata fi...

    Recruitment Genius: Telesales Executive - OTE £26,000+

    £16000 - £26000 per annum: Recruitment Genius: A Telesales Executive is requir...

    Day In a Page

    Seifeddine Rezgui: What motivated a shy student to kill 38 holidaymakers in Tunisia?

    Making of a killer

    What motivated a shy student to kill 38 holidaymakers in Tunisia?
    UK Heatwave: Temperatures on the tube are going to exceed the legal limit for transporting cattle

    Just when you thought your commute couldn't get any worse...

    Heatwave will see temperatures on the Tube exceed legal limit for transporting cattle
    Exclusive - The Real Stories of Migrant Britain: Swapping Bucharest for London

    The Real Stories of Migrant Britain

    Meet the man who swapped Romania for the UK in a bid to provide for his family, only to discover that the home he left behind wasn't quite what it seemed
    Cheaper energy on the way, but it's not all sunshine and rainbows

    Cheaper energy on the way, but it's not all sunshine and rainbows

    Solar power will help bring down electricity prices over the next five years, according to a new report. But it’s cheap imports of ‘dirty power’ that will lower them the most
    Katy Perry prevented from buying California convent for $14.5m after nuns sell to local businesswoman instead

    No grace of God for Katy Perry as sisters act to stop her buying convent

    Archdiocese sues nuns who turned down star’s $14.5m because they don’t approve of her
    Ajmer: The ancient Indian metropolis chosen to be a 'smart city' where residents would just be happy to have power and running water

    Residents just want water and power in a city chosen to be a ‘smart’ metropolis

    The Indian Government has launched an ambitious plan to transform 100 of its crumbling cities
    Michael Fassbender in 'Macbeth': The Scottish play on film, from Welles to Cheggers

    Something wicked?

    Films of Macbeth don’t always end well - just ask Orson Welles... and Keith Chegwin
    10 best sun creams for body

    10 best sun creams for body

    Make sure you’re protected from head to toe in the heatwave
    Wimbledon 2015: Nick Bollettieri - Milos Raonic has ability to get to the top but he must learn to handle pressure in big games

    Nick Bollettieri's Wimbledon files

    Milos Raonic has ability to get to the top but he must learn to handle pressure in big games
    Women's World Cup 2015: How England's semi-final success could do wonders for both sexes

    There is more than a shiny trophy to be won by England’s World Cup women

    The success of the decidedly non-famous females wearing the Three Lions could do wonders for a ‘man’s game’ riddled with cynicism and greed
    How to stop an asteroid hitting Earth: Would people co-operate to face down a global peril?

    How to stop an asteroid hitting Earth

    Would people cooperate to face a global peril?
    Just one day to find €1.6bn: Greece edges nearer euro exit

    One day to find €1.6bn

    Greece is edging inexorably towards an exit from the euro
    New 'Iron Man' augmented reality technology could help surgeons and firefighters, say scientists

    'Iron Man' augmented reality technology could become reality

    Holographic projections would provide extra information on objects in a person's visual field in real time
    Sugary drinks 'are killing 184,000 adults around the world every year'

    Sugary drinks are killing 184,000 adults around the world every year

    The drinks that should be eliminated from people's diets
    Pride of Place: Historians map out untold LGBT histories of locations throughout UK

    Historians map out untold LGBT histories

    Public are being asked to help improve the map